

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

宜昌東陽光長江藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 01558)

**VOLUNTARY ANNOUNCEMENT
ANNOUNCEMENT ON SUCCESSFUL BID
FOR THE CENTRALIZED PROCUREMENT**

This is a voluntary announcement made by YiChang HEC ChangJiang Pharmaceutical Co., Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”).

The board of directors of the Company announces that, on 17 January 2020, the Company participated in the tender process in respect of the Second National Centralized Procurement of Pharmaceuticals (第二批國家組織藥品集中採購) organized by the National Organization Office for the Centralized Procurement and Usage of Pharmaceuticals* (國家組織藥品集中採購和使用聯合採購辦公室) (the “**Joint Procurement Office**”). The Fudosteine Tablets of the Company, the Moxifloxacin Hydrochloride Tablets and Olmesartan Medoxomil Tablets of Dongguan Yangzhikang Pharmaceutical Co., Ltd.* (東莞市陽之康醫藥有限責任公司) (a wholly-owned subsidiary of the Company) have won the bid for the centralized procurement. The relevant information is disclosed as follows:

Number	Name of Product	Indication	Number of successful tenders	Tendering specification	Tendering Price (RMB)	Successful tenders under the Group
1	Fudosteine Tablets	For the treatment of respiratory diseases to loosen phlegm, such as chronic asthmatic bronchitis, chronic bronchitis, bronchiectasis, tuberculosis, pneumoconiosis and pneumonia	3	0.2g x 20 tablet/box	RMB13.08/box	YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

Number	Name of Product	Indication	Number of successful tenders	Tendering specification	Tendering Price (RMB)	Successful tenders under the Price Group
2	Moxifloxacin Hydrochloride Tablet	For the treatment of infections caused by sensitive bacteria in adults (18 years or older), such as acute bacterial sinusitis, complex skin and skin tissue infections, etc.	5	0.4g x 3 tablet/box 0.4g x 6 tablet/box	RMB6.66/box RMB12.99/box	Dongguan Yangzhikang Pharmaceutical Co., Ltd.* (東莞市陽之康醫藥有限責任公司)
3	Olmesartan Medoxomil Tablets	For treatment of hypertension	4	20mg x 28 tablet/box	RMB17.08/box	Dongguan Yangzhikang Pharmaceutical Co., Ltd.* (東莞市陽之康醫藥有限責任公司)

Since the market corresponding to the indications of Fudosteine Tablets, Moxifloxacin Hydrochloride Tablets and Olmesartan Medoxomil Tablets is large, as the price of the three medicines decreases, the penetration rate among patients will increase, and the sales volume of medicines is expected to increase significantly, and the market potential is huge. As and when Company sign and implement the purchase agreement in the future, the Company's market share of these three medicines will expand rapidly, boosting the sales volume of the related products, promoting the Company's domestic market development, and enhancing the Company's brand influence. The Company's income structure will also be improved, which will have a positive impact on the future operating performance of the Company.

Subsequent matters such as the signing of the purchase agreement for the above products are still uncertain. The Company will pay close attention to the progress of such matter and perform its obligation of information disclosure in a timely manner. Investors are advised to exercise in caution when making decisions and pay attention to investment risks.

This announcement is made by the Group on a voluntary basis to inform the investors of the latest business development of the Group and does not constitute, nor is intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

On behalf of the Board
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
TANG Xinfa
Chairman

Hubei, the PRC
17 January 2020

* For identification purposes only

As of the date of this announcement, the Board of the Company consists of Mr. JIANG Juncai, Mr. WANG Danjin, Mr. CHEN Yangui and Mr. LI Shuang as executive Directors; Mr. TANG Xinfu and Mr. Eddy HUANG as non-executive Directors; and Mr. TANG Jianxin, Mr. FU Hailiang and Mr. ZHAO Dayao as independent non-executive Directors.